$TBPH
Theravance Biopharma Inc Stock $tbph

$tbph Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000155837024002267 Filed on March 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$14.50M	$17.57M	$57.42M
YoY Change	39.22%	19.91%	11.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.74M	$15.49M	$70.10M
YoY Change	-12.72%	-2.98%	4.51%
% of Gross Profit
Research & Development	$8.968M	$8.314M	$40.62M
YoY Change	-38.46%	-43.45%	-35.92%
% of Gross Profit
Depreciation & Amortization	$432.0K	$392.0K	$1.900M
YoY Change	-30.88%	-40.52%	-26.92%
% of Gross Profit
Operating Expenses	$25.71M	$23.81M	$110.7M
YoY Change	-27.23%	-25.79%	-22.74%
Operating Profit	-$11.21M	-$6.240M	-$56.04M
YoY Change	-55.01%	-64.2%	-39.06%
Interest Expense	$629.0K	$1.224M	$6.766M
YoY Change	14.36%	-61.41%	6.23%
% of Operating Profit
Other Income/Expense, Net	$1.434M		$9.116M
YoY Change	-51.86%		6.68%
Pretax Income	-$10.40M	-$5.017M	-$49.27M
YoY Change	-53.73%	-64.82%	-46.92%
Income Tax	$1.300M	$3.494M	$5.924M
% Of Pretax Income
Net Earnings	-$11.66M	-$8.511M	-$55.19M
YoY Change	-47.19%	-17.86%	-106.33%
Net Earnings / Revenue	-80.42%	-48.45%	-96.11%
Basic Earnings Per Share	-$0.24	-$0.17	-$1.00
Diluted Earnings Per Share	-$0.24	-$0.17	-$1.00
COMMON SHARES
Basic Shares Outstanding	48.16M	49.80M	55.30M
Diluted Shares Outstanding	48.28M		55.30M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.98M	$102.4M	$102.4M
YoY Change	-58.56%	-68.72%	-68.72%
Cash & Equivalents	$53.84M	$102.4M	$102.4M
Short-Term Investments	$46.14M	$62.88M	$62.88M
Other Short-Term Assets	$9.655M	$13.64M	$13.64M
YoY Change	23.7%	48.35%	48.35%
Inventory
Prepaid Expenses
Receivables	$14.66M	$17.47M	$17.47M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$124.3M	$133.5M	$133.5M
YoY Change	-52.44%	-62.22%	-62.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.717M	$45.36M	$45.36M
YoY Change	-27.98%	281.94%	-12.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.896M	$203.1M	$203.1M
YoY Change	-34.71%	2843.95%	0.58%
Total Long-Term Assets	$247.0M	$248.5M	$248.5M
YoY Change	-10.89%	-2.16%	-2.16%
TOTAL ASSETS
Total Short-Term Assets	$124.3M	$133.5M	$133.5M
Total Long-Term Assets	$247.0M	$248.5M	$248.5M
Total Assets	$371.3M	$382.0M	$382.0M
YoY Change	-31.05%	-37.11%	-37.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.686M	$1.524M	$1.524M
YoY Change	-36.69%	-1.93%	-1.93%
Accrued Expenses	$13.49M	$16.75M	$16.75M
YoY Change	-42.61%	-38.27%	-38.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.66M	$24.77M	$24.77M
YoY Change	-17.27%	-13.75%	-13.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.445M	$144.2M	$144.2M
YoY Change	-29.08%	8604.71%	5.37%
Total Long-Term Liabilities	$5.445M	$144.2M	$144.2M
YoY Change	-29.08%	8604.71%	5.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.66M	$24.77M	$24.77M
Total Long-Term Liabilities	$5.445M	$144.2M	$144.2M
Total Liabilities	$27.11M	$169.0M	$169.0M
YoY Change	-19.95%	456.45%	2.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$920.8M	-$909.1M
YoY Change	5.11%	6.46%
Common Stock	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$204.9M	$213.0M	$213.0M
YoY Change
Total Liabilities & Shareholders Equity	$371.3M	$382.0M	$382.0M
YoY Change	-31.05%	-37.11%	-37.11%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.66M	-$8.511M	-$55.19M
YoY Change	-47.19%	-17.86%	-106.33%
Depreciation, Depletion And Amortization	$432.0K	$392.0K	$1.900M
YoY Change	-30.88%	-40.52%	-26.92%
Cash From Operating Activities	-$1.022M	-$854.0K	-$27.00M
YoY Change	-90.89%	-99.31%	-85.56%
INVESTING ACTIVITIES
Capital Expenditures	$91.00K	$677.0K	$2.488M
YoY Change	-90.3%	154.51%	334.97%
Acquisitions
YoY Change
Other Investing Activities	$17.12M	$1.000K	-$30.21M
YoY Change	-140.65%	-100.0%	-102.62%
Cash From Investing Activities	$17.03M	-$677.0K	-$32.70M
YoY Change	-139.56%	-101.73%	-102.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.716M	-30.61M	-198.9M
YoY Change	-96.95%	-13.71%	-73.78%
NET CHANGE
Cash From Operating Activities	-1.022M	-854.0K	-27.00M
Cash From Investing Activities	17.03M	-677.0K	-32.70M
Cash From Financing Activities	-1.716M	-30.61M	-198.9M
Net Change In Cash	14.29M	-32.14M	-258.6M
YoY Change	-112.93%	-73.3%	-224.21%
FREE CASH FLOW
Cash From Operating Activities	-$1.022M	-$854.0K	-$27.00M
Capital Expenditures	$91.00K	$677.0K	$2.488M
Free Cash Flow	-$1.113M	-$1.531M	-$29.49M
YoY Change	-90.85%	-98.77%	-84.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.35
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.28
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.17
CY2023Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.17
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.55
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.35
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.21
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.21
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.21
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.24
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	12.35
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.06
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	12.14
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001583107
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65227000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48091000
CY2023	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal Statement Of Income Extensible List DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2023Q4	tbph	Fair Value Assets Level2 To Level1 Transfer Amount FairValueAssetsLevel2ToLevel1TransferAmount	0
CY2021Q3	us-gaap	Lessee Operating Sublease Option To Extend LesseeOperatingSubleaseOptionToExtend	false
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36033
CY2023	dei	Entity Registrant Name EntityRegistrantName	THERAVANCE BIOPHARMA, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	KY
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1226628
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	C/O Theravance Biopharma US, Inc.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	901 Gateway Boulevard
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	808-6000
CY2023	dei	Security12b Title Security12bTitle	Ordinary Share $0.00001 Par Value
CY2023	dei	Trading Symbol TradingSymbol	TBPH
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	458800000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48164708
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39545000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298172000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	62881000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29312000
CY2023Q4	tbph	Receivables From Collaboration Partners ReceivablesFromCollaborationPartners	17474000
CY2022Q4	tbph	Receivables From Collaboration Partners ReceivablesFromCollaborationPartners	16785000
CY2023Q4	tbph	Prepaid Clinical And Development Services PrepaidClinicalAndDevelopmentServices	2038000
CY2022Q4	tbph	Prepaid Clinical And Development Services PrepaidClinicalAndDevelopmentServices	1513000
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	11603000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7682000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	133541000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	353464000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9068000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11875000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36287000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40126000
CY2023Q4	tbph	Future Contingent Milestone And Royalty Assets FutureContingentMilestoneAndRoyaltyAssets	194200000
CY2022Q4	tbph	Future Contingent Milestone And Royalty Assets FutureContingentMilestoneAndRoyaltyAssets	194200000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	836000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	836000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8067000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6899000
CY2023Q4	us-gaap	Assets Assets	381999000
CY2022Q4	us-gaap	Assets Assets	607400000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1524000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1554000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6443000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10314000
CY2023Q4	tbph	Accrued Clinical And Development Expenses Current AccruedClinicalAndDevelopmentExpensesCurrent	2246000
CY2022Q4	tbph	Accrued Clinical And Development Expenses Current AccruedClinicalAndDevelopmentExpensesCurrent	4932000
CY2023Q4	tbph	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	2900000
CY2022Q4	tbph	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	4020000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3923000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6753000
CY2023Q4	tbph	Tenant Improvement Payable Current TenantImprovementPayableCurrent	6490000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1241000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1142000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24767000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28715000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45236000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45407000
CY2023Q4	tbph	Future Royalty Payment Contingencies FutureRoyaltyPaymentContingencies	27788000
CY2022Q4	tbph	Future Royalty Payment Contingencies FutureRoyaltyPaymentContingencies	25438000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	192000
CY2023Q4	tbph	Unrecognized Tax Benefits Total UnrecognizedTaxBenefitsTotal	65294000
CY2022Q4	tbph	Unrecognized Tax Benefits Total UnrecognizedTaxBenefitsTotal	64191000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5919000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1657000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48091000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65227000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1122164000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1295725000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-65000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-909104000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-853911000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	212995000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	441800000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	381999000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	607400000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57424000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51346000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40621000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63392000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	70095000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	67073000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	2743000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	12838000
CY2023	us-gaap	Operating Expenses OperatingExpenses	113459000
CY2022	us-gaap	Operating Expenses OperatingExpenses	143303000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-56035000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-91957000
CY2023	us-gaap	Interest Expense InterestExpense	2350000
CY2022	us-gaap	Interest Expense InterestExpense	6369000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3034000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9116000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8545000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49269000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92815000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5924000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-55193000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-92824000
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	1143930000
CY2022	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	178974000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	964956000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55193000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.00
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.00
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.26
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.26
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	13.11
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	13.11
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.85
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.85
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55303000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55303000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73591000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73591000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25371000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39734000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55193000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55243000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	872117000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-338573000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	128830000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	802000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39734000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3450000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	441800000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	441800000
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	197052000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	619000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25371000
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2500000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55193000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	212995000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55193000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	964956000
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-55193000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-92824000
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	2001000
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	3716000
CY2023	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	1897000
CY2022	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	681000
CY2023	tbph	Interest Accretion On Future Royalty Payment Contingencies InterestAccretionOnFutureRoyaltyPaymentContingencies	2350000
CY2022	tbph	Interest Accretion On Future Royalty Payment Contingencies InterestAccretionOnFutureRoyaltyPaymentContingencies	974000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	25371000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	39734000
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2709000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1352000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	8000
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4152000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3989000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3207000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3034000
CY2023	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	689000
CY2022	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	2720000
CY2023	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	526000
CY2022	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	-8733000
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	3921000
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	704000
CY2023	tbph	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-314000
CY2022	tbph	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-4424000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1233000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3802000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1612000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7095000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14086000
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1246000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-216000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-192000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3001000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1024000
CY2023	tbph	Period Increase Decrease Unrecognized Tax Benefits PeriodIncreaseDecreaseUnrecognizedTaxBenefits	1102000
CY2022	tbph	Period Increase Decrease Unrecognized Tax Benefits PeriodIncreaseDecreaseUnrecognizedTaxBenefits	63952000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	7547000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-525000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26997000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2425000
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-184566000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26997000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-186991000
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2488000
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	572000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	134534000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	103145000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	31435000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	158000000
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	71377000
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	17000
CY2022	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	2709000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1513000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1866000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-32697000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	58875000
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	1095134000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32697000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1154009000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	197051000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	128830000
CY2022	tbph	Proceeds From Funding For Royalty Rights ProceedsFromFundingForRoyaltyRights	24464000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	618000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	802000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2500000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3450000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-198933000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-738617000
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-20189000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-198933000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-758806000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-258627000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	208212000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299008000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90796000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40381000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299008000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	22244000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	24000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	117966000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Due to the inherent uncertainty in making estimates, actual results in future periods could differ materially from those estimates.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company invests in a variety of financial instruments and, based on its policy, limits the amount of credit exposure with any one issuer, industry, or geographic area for investments other than instruments backed by the US federal government. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s future contingent milestone and royalty assets and receivables primarily relate to amounts due under its collaboration and other agreements. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies or specific to its collaboration agreements. The Company performs periodic evaluations of its customers and generally does not require collateral. For the year ended December 31, 2023 and 2022, the Company did not experience any losses related to its receivables.</p>
CY2023	us-gaap	Advertising Expense AdvertisingExpense	5100000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	8000000.0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79500000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	76000000.0
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-55193000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-92824000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	964956000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55193000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2023	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	55303000
CY2022	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	73591000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55303000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55303000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73591000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73591000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.00
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.00
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.26
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.26
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	13.11
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	13.11
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.85
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.85
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3916000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5487000
CY2023	tbph	Profit Loss Percentage As Per Collaboration Agreement ProfitLossPercentageAsPerCollaborationAgreement	0.35
CY2023	tbph	Collaboration Arrangement Upfront Payments Receivable CollaborationArrangementUpfrontPaymentsReceivable	205000000.0
CY2023	tbph	Collaborative Arrangements Revenue CollaborativeArrangementsRevenue	216000
CY2022	tbph	Collaborative Arrangements Revenue CollaborativeArrangementsRevenue	192000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57424000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51346000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39545000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298172000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	836000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	836000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40381000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299008000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	60000.00
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	900000
CY2023Q4	tbph	Tenant Improvement Allowance TenantImprovementAllowance	6800000
CY2022Q4	tbph	Tenant Improvement Allowance TenantImprovementAllowance	8900000
CY2021Q3	tbph	Area Of Property Subleased AreaOfPropertySubleased	21000
CY2021Q3	tbph	Sublease Monthly Base Rent SubleaseMonthlyBaseRent	100000
CY2021Q3	tbph	Sublease Percentage Of Increase In Annual Base Rent SubleasePercentageOfIncreaseInAnnualBaseRent	0.03
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	89125000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	69000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	89060000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	303557000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	27000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	303542000
CY2023	tbph	Marketable Securities Maximum Contractual Maturity Period MarketableSecuritiesMaximumContractualMaturityPeriod	P6M
CY2023	tbph	Marketable Securities Average Contractual Maturity Period MarketableSecuritiesAverageContractualMaturityPeriod	P2M
CY2023Q4	tbph	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	57880000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	69000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	57880000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	69000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	37280000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	27000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	37280000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	27000
CY2023Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	71400000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30650000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44711000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21582000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32836000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9068000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11875000
CY2023	us-gaap	Depreciation Depreciation	1900000
CY2022	us-gaap	Depreciation Depreciation	2600000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1200000
CY2023Q4	tbph	Area Of Leased Space AreaOfLeasedSpace	162000
CY2023	tbph	Number Of Building Leased NumberOfBuildingLeased	2
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	13100000
CY2021Q3	tbph	Premium Over Proportionate Lease Payment Obligations PremiumOverProportionateLeasePaymentObligations	4200000
CY2021Q3	tbph	Percentage Of Excess Sublease Payments Received Shared With Lessor PercentageOfExcessSubleasePaymentsReceivedSharedWithLessor	0.50
CY2021Q3	tbph	Premium Over Proportionate Lease Payment Obligations Shared With Lessor PremiumOverProportionateLeasePaymentObligationsSharedWithLessor	2100000
CY2021Q3	tbph	Percentage Of Excess Sublease Payments Received Retained PercentageOfExcessSubleasePaymentsReceivedRetained	0.50
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36287000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40126000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3923000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6753000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45236000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45407000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	49159000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52160000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	9966000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	9312000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0864
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0863
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3897000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10940000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11198000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11479000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	11739000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	16837000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	66090000
CY2023Q4	tbph	Tenant Improvement Allowance TenantImprovementAllowance	6838000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10093000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	49159000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	0
CY2014Q2	tbph	Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans	3
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8139725
CY2023	tbph	Share Based Compensation Allocation Of Recognized Period Costs Capitalized Reversed Amount ShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedReversedAmount	800000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	1700000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25371000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39734000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25371000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39734000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	34357000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0001
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5900000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-179000000.0
CY2023Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000
CY2023	tbph	Income Loss Before Income Taxes Noncontrolling Interest IncomeLossBeforeIncomeTaxesNoncontrollingInterest	-49269000
CY2022	tbph	Income Loss Before Income Taxes Noncontrolling Interest IncomeLossBeforeIncomeTaxesNoncontrollingInterest	-92815000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2717000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-9000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3207000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5924000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1202
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	153225000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	141674000
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	21482000
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19409000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16910000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16176000
CY2023Q4	tbph	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	235381000
CY2022Q4	tbph	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	245822000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3431000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4298000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1186000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1795000
CY2023Q4	tbph	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	10946000
CY2022Q4	tbph	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	11239000
CY2023Q4	tbph	Deferred Tax Assets Prepaid Expenses DeferredTaxAssetsPrepaidExpenses	-248000
CY2022Q4	tbph	Deferred Tax Assets Prepaid Expenses DeferredTaxAssetsPrepaidExpenses	304000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4982000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	30000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	447295000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	440747000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	429850000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422325000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17445000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	18422000
CY2023Q4	tbph	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	8076000
CY2022Q4	tbph	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	8634000
CY2023Q4	tbph	Deferred Tax Liabilities Future Contingent Milestone And Royalty Assets DeferredTaxLiabilitiesFutureContingentMilestoneAndRoyaltyAssets	14512000
CY2022Q4	tbph	Deferred Tax Liabilities Future Contingent Milestone And Royalty Assets DeferredTaxLiabilitiesFutureContingentMilestoneAndRoyaltyAssets	11725000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	22588000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20359000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5143000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1937000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422300000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	429900000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75023000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	7395000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8371000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75999000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	632000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4103000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79470000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79500000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	76000000.0
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	600000
CY2023Q4	tbph	Unrecognized Tax Benefits That Can Be Relieved UnrecognizedTaxBenefitsThatCanBeRelieved	65300000
CY2022Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	250000000.0
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	325000000.0
CY2021Q3	tbph	Percentage Of Reduction In Workforce PercentageOfReductionInWorkforce	0.75
CY2022	us-gaap	Restructuring Charges RestructuringCharges	12800000
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	33000000.0
CY2023Q1	tbph	Percent Of Employee Reduction PercentOfEmployeeReduction	17
CY2023Q1	tbph	Research And Development Resource Allocation Number Of Programs ResearchAndDevelopmentResourceAllocationNumberOfPrograms	2
CY2023	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	1188000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	1188000
CY2022Q4	tbph	Guarantees And Indemnifications Liability GuaranteesAndIndemnificationsLiability	0
CY2023Q4	tbph	Guarantees And Indemnifications Liability GuaranteesAndIndemnificationsLiability	0
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10417000
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13749000
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15693000
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17565000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	35329000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	29872000
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	24453000
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	23805000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24912000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16123000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8760000
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6240000
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-22088000
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15645000
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8950000
CY2023Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8510000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-22088000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-15645000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-8950000
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-8510000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.35
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.28
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2023Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13196000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11050000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12451000
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14649000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	51698000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	37929000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	21595000
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	32081000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-38502000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26879000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9144000
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-17432000
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-41538000
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-26570000
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10460000
CY2022Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-14256000
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	15592000
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	18379000
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	927091000
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3894000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25946000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8191000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	916631000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10362000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.55
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.35
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.21
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.21
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.21
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.24
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	12.35
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.06
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	12.14
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023	tbph	Profit Loss Percentage As Per Collaboration Agreement ProfitLossPercentageAsPerCollaborationAgreement	0.35

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
tbph-20231231_cal.xml	Edgar Link	unprocessable
0001558370-24-002267-index-headers.html	Edgar Link	pending
0001558370-24-002267-index.html	Edgar Link	pending
0001558370-24-002267.txt	Edgar Link	pending
0001558370-24-002267-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tbph-20231231.xsd	Edgar Link	pending
tbph-20231231x10k.htm	Edgar Link	pending
tbph-20231231x10k006.jpg	Edgar Link	pending
tbph-20231231x10k007.jpg	Edgar Link	pending
tbph-20231231x10k008.jpg	Edgar Link	pending
tbph-20231231x10k009.jpg	Edgar Link	pending
tbph-20231231xex10d39.htm	Edgar Link	pending
tbph-20231231xex10d39001.jpg	Edgar Link	pending
tbph-20231231xex10d39002.jpg	Edgar Link	pending
tbph-20231231xex10d39003.jpg	Edgar Link	pending
tbph-20231231xex10d39004.jpg	Edgar Link	pending
tbph-20231231xex21d1.htm	Edgar Link	pending
tbph-20231231xex23d1.htm	Edgar Link	pending
tbph-20231231xex31d1.htm	Edgar Link	pending
tbph-20231231xex31d2.htm	Edgar Link	pending
tbph-20231231xex32.htm	Edgar Link	pending
tbph-20231231xex97d1.htm	Edgar Link	pending
tbph-20231231_def.xml	Edgar Link	unprocessable
tbph-20231231_lab.xml	Edgar Link	unprocessable
tbph-20231231_pre.xml	Edgar Link	unprocessable
tbph-20231231x10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TBPH
Theravance Biopharma Inc Stock $tbph

2024 Q1 Form 10-K Financial Statement

#000155837024002267 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBPH Theravance Biopharma Inc Stock $tbph

2024 Q1 Form 10-K Financial Statement

#000155837024002267 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBPH
Theravance Biopharma Inc Stock $tbph